Exelixis, Inc. (NASDAQ: EXEL) today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Exelixis (EXEL) PT Raised to $35 at SunTrust Robinson HumphreyOctober 16, 2017 11:16 AM Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular CarcinomaOctober 16, 2017 6:58 AM